Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® box 2,
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Cipla Limited (BSE: 5
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
Perkin Elmer a US based multinational company mostly involed in the business of Human and Environmental Health, has launched its NeoBase 2 non-derivatized tandem mass spectrometry (MS/MS) kit, which recently obtained the CE mark. The kit analyzes newborn heel prick blood samples dried on filter paper, and is used with a tandem mass spectrometer.
PerkinElmer Inc, Waltham, Mass, has launched its NeoBase 2 non-derivatized tandem mass spectrometry (MS/MS) kit, which recently obtained the CE mark. The in vitro diagnostic (IVD) kit is intended for the semiquantitative measurement and evaluation of acylcarnitine, amino acid, free carnitine lysophospholipid, nucleoside, and succinylacetone concentrations. The kit analyzes newborn heel prick blood samples dried on filter paper, and is used with a tandem mass spectrometer.
PerkinElmer Inc, Waltham, Mass, has launched its NeoBase 2 non-derivatized tandem mass spectrometry (MS/MS) kit, which recently obtained the CE mark. The in vitro diagnostic (IVD) kit is intended for the semiquantitative measurement and evaluation of acylcarnitine, amino acid, free carnitine lysophospholipid, nucleoside, and succinylacetone concentrations.
The NeoBase2 MS/MS kit can test for up to 57 analytes, including markers for screening of X-linked adrenoleukodystrophy, the most common peroxisomal disorder. It can also screen for adenosine deaminase severe combined immunodeficiency (ADA-SCID), which is caused by a deficiency of the enzyme ADA and is the second most common SCID.
Linh Hoang, MD, PhD, vice president for neonatal screening at PerkinElmer, Says, “As the industry leader in mass spectrometry-based newborn screening, we continue to evolve our technologies to meet the needs of laboratories worldwide,especially as more countries mandate certain metabolic tests such as those for SCIDs and peroxisomal disorders,”
“As these labs face pressure to screen for more disorders in less time and with limited resources, they are seeking advanced technology to expand their MS/MS testing capabilities.”
For more information:Click here
